Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice

Results from Japanese observational cohort

Teruo Inamoto, Haruhito Azuma, Shiro Hinotsu, Taiji Tsukamoto, Mototsugu Oya, Osamu Ogawa, Tadaichi Kitamura, Suzuki Kazuhiro, Seiji Naito, Mikio Namiki, Kazuo Nishimura, Yoshihiko Hirao, Michiyuki Usami, Masaru Murai, Hideyuki Akaza

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: Primary androgen deprivation therapy (PADT) had been used extensively in Japan than in the USA and European countries regardless of the disease risk or patient's age. To illustrate the consequence of PADT from daily clinical practice, we evaluated the relationship among age, disease risk, and survival of patients with prostate cancer treated by PADT in largest Asian cohort. Patients and methods: The 19,246 men subjected to PADT enrolled in the Japan Study Group of Prostate Cancer were enrolled for the present analysis. Patients were divided into four groups based on age at diagnosis: age <66, 66-70, 71-75, and >75. Risk was stratified according to the Japan Cancer of the Prostate Risk Assessment (J-CAPRA). Multivariate competing risks regression analysis was performed for OS and PFS. Results: There was downward stage migration over age. Among men aged >75 years, 34.1 % had nodal or distant metastatic disease. In contrast, 56.0 % of patients aged <66 years presented with advanced disease. The modality of hormonal therapy varied with age across risk groups; the younger age group showed a higher proportion of maximal androgen blockade, while the proportion of monotherapy use was higher in older men. The likelihood of low-risk disease by J-CAPRA classification increased significantly with increasing age (p < 0.0001 by Pearson's chi-square test). The same as OS, the PFS rate increased with age until after the age of 75. Men aged 71-75 had better survival rates even after adjustments for treatment modality alone, or for treatment modality plus disease risk. Conclusions: Age cohorts do affect orientation toward favorable disease course after PADT with men aged 71-75 being benefiting more from PADT than other age groups.

Original languageEnglish
Pages (from-to)1197-1204
Number of pages8
JournalJournal of Cancer Research and Clinical Oncology
Volume140
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Androgens
Prostatic Neoplasms
Survival
Japan
Therapeutics
Age Groups
Chi-Square Distribution
Survival Rate
Regression Analysis

Keywords

  • ADT
  • Age at diagnosis
  • CaP

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice : Results from Japanese observational cohort. / Inamoto, Teruo; Azuma, Haruhito; Hinotsu, Shiro; Tsukamoto, Taiji; Oya, Mototsugu; Ogawa, Osamu; Kitamura, Tadaichi; Kazuhiro, Suzuki; Naito, Seiji; Namiki, Mikio; Nishimura, Kazuo; Hirao, Yoshihiko; Usami, Michiyuki; Murai, Masaru; Akaza, Hideyuki.

In: Journal of Cancer Research and Clinical Oncology, Vol. 140, No. 7, 2014, p. 1197-1204.

Research output: Contribution to journalArticle

Inamoto, T, Azuma, H, Hinotsu, S, Tsukamoto, T, Oya, M, Ogawa, O, Kitamura, T, Kazuhiro, S, Naito, S, Namiki, M, Nishimura, K, Hirao, Y, Usami, M, Murai, M & Akaza, H 2014, 'Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: Results from Japanese observational cohort', Journal of Cancer Research and Clinical Oncology, vol. 140, no. 7, pp. 1197-1204. https://doi.org/10.1007/s00432-014-1638-y
Inamoto, Teruo ; Azuma, Haruhito ; Hinotsu, Shiro ; Tsukamoto, Taiji ; Oya, Mototsugu ; Ogawa, Osamu ; Kitamura, Tadaichi ; Kazuhiro, Suzuki ; Naito, Seiji ; Namiki, Mikio ; Nishimura, Kazuo ; Hirao, Yoshihiko ; Usami, Michiyuki ; Murai, Masaru ; Akaza, Hideyuki. / Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice : Results from Japanese observational cohort. In: Journal of Cancer Research and Clinical Oncology. 2014 ; Vol. 140, No. 7. pp. 1197-1204.
@article{7b2013064d9440e6a303de2065104a9a,
title = "Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: Results from Japanese observational cohort",
abstract = "Objectives: Primary androgen deprivation therapy (PADT) had been used extensively in Japan than in the USA and European countries regardless of the disease risk or patient's age. To illustrate the consequence of PADT from daily clinical practice, we evaluated the relationship among age, disease risk, and survival of patients with prostate cancer treated by PADT in largest Asian cohort. Patients and methods: The 19,246 men subjected to PADT enrolled in the Japan Study Group of Prostate Cancer were enrolled for the present analysis. Patients were divided into four groups based on age at diagnosis: age <66, 66-70, 71-75, and >75. Risk was stratified according to the Japan Cancer of the Prostate Risk Assessment (J-CAPRA). Multivariate competing risks regression analysis was performed for OS and PFS. Results: There was downward stage migration over age. Among men aged >75 years, 34.1 {\%} had nodal or distant metastatic disease. In contrast, 56.0 {\%} of patients aged <66 years presented with advanced disease. The modality of hormonal therapy varied with age across risk groups; the younger age group showed a higher proportion of maximal androgen blockade, while the proportion of monotherapy use was higher in older men. The likelihood of low-risk disease by J-CAPRA classification increased significantly with increasing age (p < 0.0001 by Pearson's chi-square test). The same as OS, the PFS rate increased with age until after the age of 75. Men aged 71-75 had better survival rates even after adjustments for treatment modality alone, or for treatment modality plus disease risk. Conclusions: Age cohorts do affect orientation toward favorable disease course after PADT with men aged 71-75 being benefiting more from PADT than other age groups.",
keywords = "ADT, Age at diagnosis, CaP",
author = "Teruo Inamoto and Haruhito Azuma and Shiro Hinotsu and Taiji Tsukamoto and Mototsugu Oya and Osamu Ogawa and Tadaichi Kitamura and Suzuki Kazuhiro and Seiji Naito and Mikio Namiki and Kazuo Nishimura and Yoshihiko Hirao and Michiyuki Usami and Masaru Murai and Hideyuki Akaza",
year = "2014",
doi = "10.1007/s00432-014-1638-y",
language = "English",
volume = "140",
pages = "1197--1204",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice

T2 - Results from Japanese observational cohort

AU - Inamoto, Teruo

AU - Azuma, Haruhito

AU - Hinotsu, Shiro

AU - Tsukamoto, Taiji

AU - Oya, Mototsugu

AU - Ogawa, Osamu

AU - Kitamura, Tadaichi

AU - Kazuhiro, Suzuki

AU - Naito, Seiji

AU - Namiki, Mikio

AU - Nishimura, Kazuo

AU - Hirao, Yoshihiko

AU - Usami, Michiyuki

AU - Murai, Masaru

AU - Akaza, Hideyuki

PY - 2014

Y1 - 2014

N2 - Objectives: Primary androgen deprivation therapy (PADT) had been used extensively in Japan than in the USA and European countries regardless of the disease risk or patient's age. To illustrate the consequence of PADT from daily clinical practice, we evaluated the relationship among age, disease risk, and survival of patients with prostate cancer treated by PADT in largest Asian cohort. Patients and methods: The 19,246 men subjected to PADT enrolled in the Japan Study Group of Prostate Cancer were enrolled for the present analysis. Patients were divided into four groups based on age at diagnosis: age <66, 66-70, 71-75, and >75. Risk was stratified according to the Japan Cancer of the Prostate Risk Assessment (J-CAPRA). Multivariate competing risks regression analysis was performed for OS and PFS. Results: There was downward stage migration over age. Among men aged >75 years, 34.1 % had nodal or distant metastatic disease. In contrast, 56.0 % of patients aged <66 years presented with advanced disease. The modality of hormonal therapy varied with age across risk groups; the younger age group showed a higher proportion of maximal androgen blockade, while the proportion of monotherapy use was higher in older men. The likelihood of low-risk disease by J-CAPRA classification increased significantly with increasing age (p < 0.0001 by Pearson's chi-square test). The same as OS, the PFS rate increased with age until after the age of 75. Men aged 71-75 had better survival rates even after adjustments for treatment modality alone, or for treatment modality plus disease risk. Conclusions: Age cohorts do affect orientation toward favorable disease course after PADT with men aged 71-75 being benefiting more from PADT than other age groups.

AB - Objectives: Primary androgen deprivation therapy (PADT) had been used extensively in Japan than in the USA and European countries regardless of the disease risk or patient's age. To illustrate the consequence of PADT from daily clinical practice, we evaluated the relationship among age, disease risk, and survival of patients with prostate cancer treated by PADT in largest Asian cohort. Patients and methods: The 19,246 men subjected to PADT enrolled in the Japan Study Group of Prostate Cancer were enrolled for the present analysis. Patients were divided into four groups based on age at diagnosis: age <66, 66-70, 71-75, and >75. Risk was stratified according to the Japan Cancer of the Prostate Risk Assessment (J-CAPRA). Multivariate competing risks regression analysis was performed for OS and PFS. Results: There was downward stage migration over age. Among men aged >75 years, 34.1 % had nodal or distant metastatic disease. In contrast, 56.0 % of patients aged <66 years presented with advanced disease. The modality of hormonal therapy varied with age across risk groups; the younger age group showed a higher proportion of maximal androgen blockade, while the proportion of monotherapy use was higher in older men. The likelihood of low-risk disease by J-CAPRA classification increased significantly with increasing age (p < 0.0001 by Pearson's chi-square test). The same as OS, the PFS rate increased with age until after the age of 75. Men aged 71-75 had better survival rates even after adjustments for treatment modality alone, or for treatment modality plus disease risk. Conclusions: Age cohorts do affect orientation toward favorable disease course after PADT with men aged 71-75 being benefiting more from PADT than other age groups.

KW - ADT

KW - Age at diagnosis

KW - CaP

UR - http://www.scopus.com/inward/record.url?scp=84904091550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904091550&partnerID=8YFLogxK

U2 - 10.1007/s00432-014-1638-y

DO - 10.1007/s00432-014-1638-y

M3 - Article

VL - 140

SP - 1197

EP - 1204

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 7

ER -